StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune r&d expenses

Research and development expenses are spending on new products and technology.

Evommune's R&D Expenses for the twelve months ending Sep 30, 2026 was $88.69M, up 24.1% year over year. For fiscal 2025 it was $74.04M, up 15.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$74.04M+15.3%
FY2024Dec 31, 2024$64.24M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$24.55M+25.0%
Q2 FY2026Jun 30, 2026$26.41M+34.5%
Q1 FY2026Mar 31, 2026$17.32M+20.6%
Q4 FY2025Dec 31, 2025$20.40M+14.4%
Q3 FY2025Sep 30, 2025$19.64M+47.8%
Q2 FY2025Jun 30, 2025$19.64M–
Q1 FY2025Mar 31, 2025$14.36M–
Q4 FY2024Dec 31, 2024$17.83M–
Q3 FY2024Sep 30, 2024$13.29M–

More Evommune figures

See a number that looks wrong?